![TRAIL, Fas Ligand, TNF and TLR3 in Cancer](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![TRAIL, Fas Ligand, TNF and TLR3 in Cancer](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
TRAIL, Fas Ligand, TNF and TLR3 in Cancer
-
- €119.99
-
- €119.99
Publisher Description
This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.
Other Books in This Series
Resistance to Molecular Therapies for Hepatocellular Carcinoma
2017
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
2018
Resistance to Targeted Therapies in Breast Cancer
2017
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
2018
Resistance to Ibritumomab in Lymphoma
2018
Cancer Stem Cell Resistance to Targeted Therapy
2019